---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000040"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T06:59:32.845917+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q3 adj EPS $2.95 (down 19.4%); raises FY23 and FY24 guidance; dividend up 4.7%

## Summary
- Q3 GAAP diluted EPS $1.00 (down 54.8% YoY); adjusted diluted EPS $2.95 (down 19.4%); net rev $13.93B (down 6.0%).
- Immunology down 11.3% as Humira fell 36.2%; Skyrizi up 52.1% and Rinvoq up 59.8% drove growth in other segments.
- Raises 2023 adj EPS guidance to $11.19-$11.23 from $10.86-$11.06; 2024 floor raised to $11.00 from $10.70.
- Dividend increased 4.7% to $1.55/quarter; payable Feb 15, 2024 to holders of record Jan 16, 2024.
- Records $2.1B pre-tax impairment on Imbruvica intangible due to IRA price negotiation; remaining carrying value $1.8B.

## SEC filing metadata
- accession: 0001551152-23-000040
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000040/0001551152-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000040/abbv-20231027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000040
- JSON: https://secwatch.observer/filing/0001551152-23-000040.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.